While in phase II trial evaluation of atezolizumab, the anti-PD-1 monoclonal antibody with the VEGF monoclonal antibody, bevacizumab in advanced MM revealed an ORR of 36.4%, with a median PFS of 5.2 months and a DCR of 59.1% [46,192]. The gene discussed is VEGFA; the disease is Miyoshi myopathy.